OTC: CLRPF - Clarity Pharmaceuticals Ltd

Rentabilität für sechs Monate: -75.5%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Clarity Pharmaceuticals Ltd

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.

weitere details
The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.claritypharmaceuticals.com
Цена ао 1.5
Preisänderung pro Tag: -6.78% (1.18)
Preisänderung pro Woche: +17.02% (0.94)
Preisänderung pro Monat: -37.29% (1.754)
Preisänderung über 3 Monate: -51.54% (2.27)
Preisänderung über sechs Monate: -75.5% (4.49)
Preisänderung pro Jahr: -42.11% (1.9)
Preisänderung seit Jahresbeginn: -62.59% (2.94)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 10.16 1
P/E 0 0
EV/EBITDA 0 0
Gesamt: 2.63

Effizienz

Name Bedeutung Grad
ROA, % -31.35 0
ROE, % -33.85 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 0 0
Rentabilität EPS, % 1.72 1
Gesamt: 4.2
Weitere Details

Institutionen Volumen Aktie, %
PFM Multi Manager Series-International Equity Fd 24827 0.01



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Alan John Taylor Ph.D. Executive Chairman 567.72k
Dr. Colin David Biggin Ph.D. MD, CEO & Executive Director 455.18k
Mr. David K. Green BEc., CA Chief Financial Officer 159.32k
Mr. Shaemus Gleason Executive Vice President of Operations N/A
Dr. Matthew Harris BSc., M.B.A., Ph.D. Chief Scientific Officer 130.94k
Michelle Parker Chief Clinical Officer N/A
Mr. Robert Vickery Company Secretary 109.28k
Ms. Lisa Sadetskaya Director of Corporate Communications.
Mary Bennett Head of Human Resource
Dr. Othon Gervasio Chief Medical Officer

Adresse: Australia, Sydney, National Innovation Centre - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.claritypharmaceuticals.com